Skip to main content
Clinical Trials/CTRI/2024/02/062253
CTRI/2024/02/062253
Not yet recruiting
Phase 3

A randomized controlled clinical study to evaluate the efficacy of Siravedha and Eranda Taila orally in Vatakanatak with special reference to Plantar Fasciitis

Dr Dipali Rohidas Shinde1 site in 1 country60 target enrollmentStarted: February 13, 2024Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Dr Dipali Rohidas Shinde
Enrollment
60
Locations
1
Primary Endpoint
Reduced pain in plantar region

Overview

Brief Summary

This study is prospective, randomized, open labelled, controlled  clinical  study to evaluate the efficacy of siravedha once a week for 3 weeks and Eranda Taila 5ml HS orally for 15 days with assesment on 0, 8th and 17th day in Vatakanatak with special reference to Plantar fasciitis. This study is conducted as PG course at single centre. The primary outcome is to study the efficacy of Siravedha and Eranda Taila oraaly in Vatakanatak with special reference to Plantar Fasciitis.

Study Design

Study Type
Interventional
Allocation
Coin toss, Lottery, toss of dice, shuffling cards etc
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients will be selected irrespective of sex, chronicity.
  • patients of age group 18-60 suffering from only vatakanatak (Plantar Fasciitis).
  • patients with pratyatma lakshana of vatakanatak vyadhi i.e pain in plantar aspect of heel, tenderness.
  • patients having pain at plantar region in presence of normal plain radiograph of foot (AP & lateral view).

Exclusion Criteria

  • Anarhas of siravedha mentioned in classics.
  • Patients having uncontrolled DM, HTN or any severe systemic diseases.
  • calcaneal stress fracture.
  • The patients clinically assessed with impaired circulation to lower extremities.
  • Patients with referred pain due to sciatica & other neurological disorders.
  • Bleeding disorders.
  • Those patients who need other emergency interventions like surgery and other means are excluded.
  • Anaemic patients.
  • HIV, HBSAG reactive patients are also excluded.
  • Malignant & immunocompromised patients are also excluded.

Outcomes

Primary Outcomes

Reduced pain in plantar region

Time Frame: 16 days

Secondary Outcomes

  • 1. Reduced tenderness in plantar region(2. Normal movements of ankle joints)

Investigators

Sponsor
Dr Dipali Rohidas Shinde
Sponsor Class
Other [self ]
Responsible Party
Principal Investigator
Principal Investigator

Dr Dipali Rohidas Shinde

Government Ayurved College and Hospital, Vazirabad, Nanded

Study Sites (1)

Loading locations...

Similar Trials